Envista Holdings Co. (NYSE:NVST) Receives Average Rating of “Hold” from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have received an average rating of “Hold” from the fifteen research firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $20.13.

NVST has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a research note on Thursday, October 31st. Leerink Partners raised shares of Envista from an “underperform” rating to a “market perform” rating and increased their target price for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Robert W. Baird upped their price target on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Wells Fargo & Company assumed coverage on Envista in a report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price objective on the stock. Finally, Jefferies Financial Group increased their price objective on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday.

Envista Stock Performance

Shares of NVST opened at $21.28 on Friday. Envista has a 12 month low of $15.15 and a 12 month high of $24.79. The firm has a market cap of $3.66 billion, a PE ratio of -2.74, a P/E/G ratio of 1.83 and a beta of 1.33. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The stock has a fifty day moving average price of $19.99 and a 200-day moving average price of $18.78.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. The business had revenue of $601.00 million during the quarter, compared to the consensus estimate of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 earnings per share. Equities research analysts predict that Envista will post 0.72 earnings per share for the current fiscal year.

Institutional Trading of Envista

Institutional investors and hedge funds have recently modified their holdings of the business. Ariel Investments LLC raised its holdings in Envista by 11.0% in the 2nd quarter. Ariel Investments LLC now owns 9,871,152 shares of the company’s stock valued at $164,157,000 after acquiring an additional 978,952 shares during the last quarter. Nuance Investments LLC increased its holdings in shares of Envista by 4.4% during the 3rd quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock worth $145,168,000 after buying an additional 308,221 shares during the last quarter. Clarkston Capital Partners LLC boosted its holdings in Envista by 0.4% in the third quarter. Clarkston Capital Partners LLC now owns 4,347,300 shares of the company’s stock valued at $85,903,000 after acquiring an additional 17,085 shares during the last quarter. Franklin Resources Inc. grew its position in Envista by 26.5% during the third quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock valued at $78,480,000 after acquiring an additional 830,861 shares during the period. Finally, Pacer Advisors Inc. increased its stake in Envista by 22.2% during the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock worth $69,749,000 after acquiring an additional 642,401 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.